Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29892461 | 1.00 | MME (0.39) | MMEPRMT1OPRM1OPRD1PDCD1LG2 | |
| SCHEMBL29876444 | 1.00 | MME (0.39) | MMEPRMT1OPRM1OPRD1PDCD1LG2 | |
| SCHEMBL31121552 | 1.00 | MME (0.39) | MMEPRMT1OPRM1OPRD1PDCD1LG2 | |
| SCHEMBL30593912 | 0.90 | OPRM1 (0.43) | MMEPRMT1OPRM1OPRD1PDCD1LG2 | |
| SCHEMBL31031477 | 0.85 | ALDH1A1 (0.41) | MMETERT | |
| SCHEMBL6749006 | 0.85 | TGFBR1 (0.42) | MMEOPRM1OPRD1TGFBR1QRFPR | |
| SCHEMBL31187165 | 0.85 | TGFBR1 (0.42) | MMEOPRM1OPRD1TGFBR1QRFPR | |
| SCHEMBL17874144 | 0.85 | TGFBR1 (0.42) | MMEOPRM1OPRD1TGFBR1QRFPR | |
| SCHEMBL6749004 | 0.85 | TGFBR1 (0.42) | MMEOPRM1OPRD1TGFBR1QRFPR | |
| SCHEMBL1635449 | 0.85 | TGFBR1 (0.42) | MMEOPRM1OPRD1TGFBR1QRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528872-B2 | De novo binding domain containing polypeptides and uses thereof | ARCELLX, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250382380-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250353920-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250353908-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250320271-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12421291-B2 | D-domain containing polypeptides and uses thereof | ARCELLX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4600353-A2 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | Arcellx, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4596575-A2 | MULTIFUNCTIONAL IMMUNE CELL THERAPIES | Arcellx, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12358995-B2 | De novo binding domain containing polypeptides and uses thereof | ARCELLX, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3710067-B1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX INC (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20240124605-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11827716-B2 | D-domain containing polypeptides and uses thereof | ARCELLX, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11730763-B2 | Multifunctional immune cell therapies | ARCELLX, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230250185-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX, INC. | 2023-08-10 | — | — | US | disclosed |
| WO-2023086983-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230125550-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11464803-B2 | D-domain containing polypeptides and uses thereof | ARCELLX, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-11377482-B2 | D-domain containing polypeptides and uses thereof | ARCELLX, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11318165-B2 | D-domain containing polypeptides and uses thereof | ARCELLX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20220056105-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX, INC. | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421291-B2 | D-domain containing polypeptides and uses thereof | CD2BP2, PDIA6, BCAP31 | MME 1268/4885PRMT1 3999/4885OPRM1 3522/4885 |
| US-12528872-B2 | De novo binding domain containing polypeptides and uses thereof | CD2BP2, PHAX, VSIG8 | MME 2197/4885PRMT1 1967/4885OPRM1 4022/4885 |
| US-11464803-B2 | D-domain containing polypeptides and uses thereof | CD2BP2, PDIA6, BCAP31 | MME 1268/4885PRMT1 3999/4885OPRM1 3522/4885 |
| US-11730763-B2 | Multifunctional immune cell therapies | CD47, HAVCR2, ICOS | MME 2859/4885PRMT1 589/4885OPRM1 4240/4885 |
| US-20250320271-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | CD2BP2, PDIA6, BCAP31 | MME 1268/4885PRMT1 3999/4885OPRM1 3522/4885 |
| US-20230125550-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | CD2BP2, PDIA6, BCAP31 | MME 1268/4885PRMT1 3999/4885OPRM1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.